The enzymatic conversion of progesterone and testosterone by the enzyme 5alpha-reductase exerts a crucial role in the control of nervous function. The effects of finasteride in the brain, an inhibitor of this enzyme used for the treatment of human benign prostatic hyperplasia and androgenic alopecia, have been poorly explored. Therefore, the effects of a subchronic treatment with finasteride at low doses (3 mg/kg/day) and the consequences of its withdrawal on neuroactive steroid levels in plasma, cerebrospinal fluid and some brain regions as well as on the expression of classical and non-classical steroid receptors have been evaluated in male rats. After subchronic treatment (i.e., for 20 days) the following effects were detected: (i) depending on the compartment considered, alteration in the levels of neuroactive steroids, not only in 5alpha-reduced metabolites but also in its precursors and in neuroactive steroids from other steroidogenic pathways and (ii) an upregulation of the androgen receptor in the cerebral cortex and beta3 subunit of the GABA-A receptor in the cerebellum. One month after the last treatment (i.e., withdrawal period), some of these effects persisted (i.e., the upregulation of the androgen receptor in the cerebral cortex, an increase of dihydroprogesterone in the cerebellum, a decrease of dihydrotestosterone in plasma). Moreover, other changes in neuroactive steroid levels, steroid receptors (i.e., an upregulation of the estrogen receptor alpha and a downregulation of the estrogen receptor beta in the cerebral cortex) and GABA-A receptor subunits (i.e., a decrease of alpha 4 and beta 3 mRNA levels in the cerebral cortex) were detected. These findings suggest that finasteride treatment may have broad consequences for brain function.

Keywords:
Testosterone, Metabolites, Steroid receptor, Neuroactive steroids, Finasteride, 5alpha-reductase, Androgen receptor, Estrogen receptor, GABA-A receptor , Brain
1.
Melcangi RC, Garcia-Segura LM, Mensah-Nyagan AG: Neuroactive steroids: state of the art and new perspectives. Cell Mol Life Sci 2008;65:777-797.
2.
Finn DA, Beadles-Bohling AS, Beckley EH, Ford MM, Gililland KR, Gorin-Meyer RE, Wiren KM: A new look at the 5alpha-reductase inhibitor finasteride. CNS Drug Rev 2006;12:53-76.
3.
Traish AM: 5alpha-reductases in human physiology: an unfolding story. Endocr Pract 2012;18:965-975.
4.
Cantagrel V, Lefeber DJ, Ng BG, et al: SRD5A3 is required for converting polyprenol to dolichol and is mutated in a congenital glycosylation disorder. Cell 2010;142:203-217.
5.
Melcangi RC, Panzica G, Garcia-Segura LM: Neuroactive steroids: focus on human brain. Neuroscience 2011;191:1-5.
6.
Panzica GC, Balthazart J, Frye CA, Garcia-Segura LM, Herbison AE, Mensah-Nyagan AG, McCarthy MM, Melcangi RC: Milestones on steroids and the nervous system: 10 years of basic and translational research. J Neuroendocrinol 2012;24:1-15.
7.
Melcangi RC, Panzica GC: Allopregnanolone: state of the art. Prog Neurobiol 2014;113:1-5.
8.
Ciriza I, Carrero P, Frye CA, Garcia-Segura LM: Reduced metabolites mediate neuroprotective effects of progesterone in the adult rat hippocampus. The synthetic progestin medroxyprogesterone acetate (Provera) is not neuroprotective. J Neurobiol 2006;66:916-928.
9.
Ford MM, Yoneyama N, Strong MN, Fretwell A, Tanchuck M, Finn DA: Inhibition of 5- alpha-reduced steroid biosynthesis impedes acquisition of ethanol drinking in male C57BL/6J mice. Alcohol Clin Exp Res 2008;32:1408-1416.
10.
Biagini G, Longo D, Baldelli E, Zoli M, Rogawski MA, Bertazzoni G, Avoli M: Neurosteroids and epileptogenesis in the pilocarpine model: evidence for a relationship between P450scc induction and length of the latent period. Epilepsia 2009;50(suppl 1):53-58.
11.
Atif F, Sayeed I, Yousuf S, Ishrat T, Hua F, Wang J, Brat DJ, Stein DG: Progesterone inhibits the growth of human neuroblastoma: in vitro and in vivo evidence. Mol Med 2011;17:1084-1094.
12.
Bortolato M, Devoto P, Roncada P, Frau R, Flore G, Saba P, Pistritto G, Soggiu A, Pisanu S, Zappala A, Ristaldi MS, Tattoli M, Cuomo V, Marrosu F, Barbaccia ML: Isolation rearing-induced reduction of brain 5alpha-reductase expression: relevance to dopaminergic impairments. Neuropharmacology 2011;60:1301-1308.
13.
Paris JJ, Brunton PJ, Russell JA, Walf AA, Frye CA: Inhibition of 5alpha-reductase activity in late pregnancy decreases gestational length and fecundity and impairs object memory and central progestogen milieu of juvenile rat offspring. J Neuroendocrinol 2011;23:1079-1090.
14.
Darbra S, Modol L, Vallee M, Pallares M: Neonatal neurosteroid levels are determinant in shaping adult prepulse inhibition response to hippocampal allopregnanolone in rats. Psychoneuroendocrinology 2013;38:1397-1406.
15.
Handa RJ, Kudwa AE, Donner NC, McGivern RF, Brown R: Central 5-alpha reduction of testosterone is required for testosterone's inhibition of the hypothalamo-pituitary-adrenal axis response to restraint stress in adult male rats. Brain Res 2013;1529:74-82.
16.
Izumi Y, Svrakic N, O'Dell K, Zorumski CF: Ammonia inhibits long-term potentiation via neurosteroid synthesis in hippocampal pyramidal neurons. Neuroscience 2013;233:166-173.
17.
Modol L, Darbra S, Vallee M, Pallares M: Alteration of neonatal Allopregnanolone levels affects exploration, anxiety, aversive learning and adult behavioural response to intrahippocampal neurosteroids. Behav Brain Res 2013;241:96-104.
18.
Jeffrey M, Lang M, Gane J, Chow E, Wu C, Zhang L: Novel anticonvulsive effects of progesterone in a mouse model of hippocampal electrical kindling. Neuroscience 2014;257:65-75.
19.
Kaufman KD, Olsen EA, Whiting D, Savin R, DeVillez R, Bergfeld W, Price VH, Van Neste D, Roberts JL, Hordinsky M, Shapiro J, Binkowitz B, Gormley GJ: Finasteride in the treatment of men with androgenetic alopecia. Finasteride Male Pattern Hair Loss Study Group. J Am Acad Dermatol 1998;39:578-589.
20.
McClellan KJ, Markham A: Finasteride: a review of its use in male pattern hair loss. Drugs 1999;57:111-126.
21.
Olsen EA, Hordinsky M, Whiting D, Stough D, Hobbs S, Ellis ML, Wilson T, Rittmaster RS: The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol 2006;55:1014-1023.
22.
Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML: Adverse side effects of 5alpha-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. J Sex Med 2011;8:872-884.
23.
Irwig MS: Safety concerns regarding 5alpha reductase inhibitors for the treatment of androgenetic alopecia. Curr Opin Endocrinol Diabetes Obes 2015;22:248-253.
24.
Altomare G, Capella GL: Depression circumstantially related to the administration of finasteride for androgenetic alopecia. J Dermatol 2002;29:665-669.
25.
Rahimi-Ardabili B, Pourandarjani R, Habibollahi P, Mualeki A: Finasteride induced depression: a prospective study. BMC Clin Pharmacol 2006;6:7.
26.
Irwig MS, Kolukula S: Persistent sexual side effects of finasteride for male pattern hair loss. J Sex Med 2011;8:1747-1753.
27.
Irwig MS: Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects. J Clin Psychiatry 2012;73:1220-1223.
28.
Irwig MS: Persistent sexual side effects of finasteride: could they be permanent? J Sex Med 2012;9:2927-2932.
29.
Melcangi RC, Caruso D, Abbiati F, Giatti S, Calabrese D, Piazza F, Cavaletti G: Neuroactive steroid levels are modified in cerebrospinal fluid and plasma of post-finasteride patients showing persistent sexual side effects and anxious/depressive symptomatology. J Sex Med 2013;10:2598-2603.
30.
Caruso D, Abbiati F, Giatti S, Romano S, Fusco L, Cavaletti G, Melcangi RC: Patients treated for male pattern hair with finasteride show, after discontinuation of the drug, altered levels of neuroactive steroids in cerebrospinal fluid and plasma. J Steroid Biochem Mol Biol 2015;146:74-79.
31.
Lebedev SV, Blinov DV, Petrov SV: Spatial characteristics of cisterna magna in rats and novel technique for puncture with a stereotactic manipulator. Bull Exp Biol Med 2004;137:635-638.
32.
Caruso D, Pesaresi M, Abbiati F, Calabrese D, Giatti S, Garcia-Segura LM, Melcangi RC: Comparison of plasma and cerebrospinal fluid levels of neuroactive steroids with their brain, spinal cord and peripheral nerve levels in male and female rats. Psychoneuroendocrinology 2013;38:2278-2290.
33.
Chomczynski P, Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
34.
Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254.
35.
Zhang MG, Wu W, Zhang CM, Wang XJ, Gao PJ, Lu YL, Shen ZJ: Effects of oral finasteride on erectile function in a rat model. J Sex Med 2012;9:1328-1336.
36.
Kiyokage E, Toida K, Suzuki-Yamamoto T, Ishimura K: Localization of 5alpha-reductase in the rat main olfactory bulb. J Comp Neurol 2005;493:381-395.
37.
Agis-Balboa RC, Pinna G, Zhubi A, Maloku E, Veldic M, Costa E, Guidotti A: Characterization of brain neurons that express enzymes mediating neurosteroid biosynthesis. Proc Natl Acad Sci USA 2006;103:14602-14607.
38.
Kiyokage E, Toida K, Suzuki-Yamamoto T, Ishimura K: Cellular localization of 5alpha-reductase in the rat cerebellum. J Chem Neuroanat 2014;59-60:8-16.
39.
Sanchez P, Torres JM, Gavete P, Ortega E: Effects of swim stress on mRNA and protein levels of steroid 5alpha-reductase isozymes in prefrontal cortex of adult male rats. Neurochem Int 2008;52:426-431.
40.
Agis-Balboa RC, Guidotti A, Pinna G: 5alpha-reductase type I expression is downregulated in the prefrontal cortex/Brodmann's area 9 (BA9) of depressed patients. Psychopharmacology (Berlin) 2014;231:3569-3580.
41.
Castelli MP, Casti A, Casu A, Frau R, Bortolato M, Spiga S, Ennas MG: Regional distribution of 5alpha-reductase type 2 in the adult rat brain: an immunohistochemical analysis. Psychoneuroendocrinology 2013;38:281-293.
42.
Duskova M, Hill M, Starka L: Changes of metabolic profile in men treated for androgenetic alopecia with 1 mg finasteride. Endocr Regul 2010;44:3-8.
43.
Mukai Y, Higashi T, Nagura Y, Shimada K: Studies on neurosteroids XXV. Influence of a 5alpha-reductase inhibitor, finasteride, on rat brain neurosteroid levels and metabolism. Biol Pharm Bull 2008;31:1646-1650.
44.
Charlier TD, Cornil CA, Patte-Mensah C, Meyer L, Mensah-Nyagan AG, Balthazart J: Local modulation of steroid action: rapid control of enzymatic activity. Front Neurosci 2015;9:83.
45.
Hedstrom H, Bixo M, Nyberg S, Spigset O, Zingmark E, Backstrom T: Studies of pharmacokinetic and pharmacodynamic properties of isoallopregnanolone in healthy women. Psychopharmacology (Berlin) 2009;203:85-98.
46.
Bengtsson SK, Nyberg S, Hedstrom H, Zingmark E, Jonsson B, Backstrom T, Bixo M: Isoallopregnanolone antagonize allopregnanolone-induced effects on saccadic eye velocity and self-reported sedation in humans. Psychoneuroendocrinology 2015;52:22-31.
47.
Lu SF, Mo Q, Hu S, Garippa C, Simon NG: Dehydroepiandrosterone upregulates neural androgen receptor level and transcriptional activity. J Neurobiol 2003;57:163-171.
48.
Mo Q, Lu SF, Simon NG: Dehydroepiandrosterone and its metabolites: differential effects on androgen receptor trafficking and transcriptional activity. J Steroid Biochem Mol Biol 2006;99:50-58.
49.
Mo Q, Lu S, Garippa C, Brownstein MJ, Simon NG: Genome-wide analysis of DHEA- and DHT-induced gene expression in mouse hypothalamus and hippocampus. J Steroid Biochem Mol Biol 2009;114:135-143.
50.
Hsieh JT, Chen SC, Yu HJ, Chang HC: Finasteride upregulates expression of androgen receptor in hyperplastic prostate and LNCaP cells: implications for chemoprevention of prostate cancer. Prostate 2011;71:1115-1121.
51.
Di Loreto C, La Marra F, Mazzon G, Belgrano E, Trombetta C, Cauci S: Immunohistochemical evaluation of androgen receptor and nerve structure density in human prepuce from patients with persistent sexual side effects after finasteride use for androgenetic alopecia. PLoS One 2014;9:e100237.
52.
Munetomo A, Hojo Y, Higo S, Kato A, Yoshida K, Shirasawa T, Shimizu T, Barron A, Kimoto T, Kawato S: Aging-induced changes in sex-steroidogenic enzymes and sex-steroid receptors in the cortex, hypothalamus and cerebellum. J Physiol Sci 2015;65:253-263.
53.
Canoine V, Fusani L, Schlinger B, Hau M: Low sex steroids, high steroid receptors: Increasing the sensitivity of the nonreproductive brain. Dev Neurobiol 2007;67:57-67.
54.
Yamada S, Noguchi D, Ito H, Yamanouchi K: Sex and regional differences in decrease of estrogen receptor alpha-immunoreactive cells by estrogen in rat hypothalamus and midbrain. Neurosci Lett 2009;463:135-139.
55.
Mitterling KL, Spencer JL, Dziedzic N, Shenoy S, McCarthy K, Waters EM, McEwen BS, Milner TA: Cellular and subcellular localization of estrogen and progestin receptor immunoreactivities in the mouse hippocampus. J Comp Neurol 2010;518:2729-2743.
56.
Reyes-Guerrero G, Guzman C, Garcia DE, Camacho-Arroyo I, Vazquez-Garcia M: Extremely low-frequency electromagnetic fields differentially regulate estrogen receptor-alpha and -beta expression in the rat olfactory bulb. Neurosci Lett 2010;471:109-113.
57.
Langlois VS, Duarte-Guterman P, Ing S, Pauli BD, Cooke GM, Trudeau VL: Fadrozole and finasteride exposures modulate sex steroid- and thyroid hormone-related gene expression in Silurana (Xenopus) tropicalis early larval development. Gen Comp Endocrinol 2010;166:417-427.
58.
Belelli D, Lambert JJ: Neurosteroids: endogenous regulators of the GABA(A) receptor. Nat Rev Neurosci 2005;6:565-575.
59.
Gunn BG, Cunningham L, Mitchell SG, Swinny JD, Lambert JJ, Belelli D: GABA receptor-acting neurosteroids: a role in the development and regulation of the stress response. Front Neuroendocrinol 2014;36:28-48.
60.
Smith SS, Shen H, Gong QH, Zhou X: Neurosteroid regulation of GABA(A) receptors: focus on the alpha4 and delta subunits. Pharmacol Ther 2007;116:58-76.
61.
Darbra S, Modol L, Llido A, Casas C, Vallee M, Pallares M: Neonatal allopregnanolone levels alteration: effects on behavior and role of the hippocampus. Prog Neurobiol 2014;113:95-105.
62.
Turkmen S, Backstrom T, Wahlstrom G, Andreen L, Johansson IM: Tolerance to allopregnanolone with focus on the GABA-A receptor. Br J Pharmacol 2011;162:311-327.
63.
Giatti S, Garcia-Segura LM, Melcangi RC: New steps forward in the neuroactive steroid field. J Steroid Biochem Mol Biol 2015;38:368-370.
64.
Traish AM, Melcangi RC, Bortolato M, Garcia-Segura LM, Zitzmann M: Adverse effects of 5alpha-reductase inhibitors: What do we know, don't know, and need to know? Rev Endocr Metab Disord 2015, DOI: 10.1007/s11154-015-9319-y.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.